Anupam Rasayan India Ltd., a leading player in custom synthesis and specialty chemicals, has reported a significant 65% year-on-year increase in total revenue for the financial year ending March 31, 2026. The company achieved a total revenue of ₹23,836 million in FY26, up from ₹14,485 million in the previous fiscal year.
The company’s EBITDA, including other income, rose by 32% to ₹5,430 million in FY26 compared to ₹4,123 million in FY25. However, the EBITDA margin for the year stood at 23%, a decrease from 28% in the previous year. Profit After Tax (PAT) also saw a substantial increase, reaching ₹2,222 million in FY26, up from ₹1,600 million in FY25.
For the quarter ended March 31, 2026, Anupam Rasayan reported a total revenue of ₹6,392 million, marking a 26% increase from ₹5,057 million in the same quarter of the previous year. The EBITDA for the quarter was ₹1,407 million, down 6% from ₹1,500 million in Q4FY25, with an EBITDA margin of 22%. The PAT for the quarter stood at ₹560 million, compared to ₹629 million in Q4FY25.
Anupam Rasayan’s Managing Director, Mr. Anand Desai, highlighted the company’s strategic achievements during the year, including the acquisition of Jayhawk Fine Chemicals in the United States, which contributed a proforma revenue of US$ 95 million. This acquisition has bolstered the company’s global manufacturing capabilities and enhanced its access to regulated markets in North America.
The company also announced a definitive agreement to acquire Bliss GVS Pharma, aiming to strengthen its pharmaceutical value chain capabilities and create synergies across its CDMO capabilities, product portfolio, and customer relationships.
Looking forward, Anupam Rasayan is poised for further growth, supported by an increasing contribution from its Performance Materials and Pharma segments, a robust product pipeline, and expanding global customer engagements.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).